China is undergoing a social, economic, and nutritional transition, and the result is a significant change in the social environments and lifestyles of people (Liu, 2008). China is becoming wealthier; however, the country faces public health risks and a growing prevalence of chronic diseases. Spending on healthcare has not kept up in pace with the economic growth that China has achieved (Liu, 2008).
There are a rising number of middle class families with improved healthcare access that are more educated and aware of the benefits of Western drugs. The Chinese pharmaceutical industry is becoming more consolidated, and stronger intellectual property rights and laws are being enforced by the Chinese government. The return of Western-educated Chinese with technical and management skills can help market drugs and establish multinational corporations (Greene, 2006).
Contents
Approval
Abstract
Dedication
Acknowledgements
Table of Contents
List of Figures
List of Tables
Glossary
1: Introduction
1.1 Objective and scope of paper
1.2 Understanding worldwide chronic disease
- 1.2.1 Various types of chronic diseases
1.2.2 Risk factors and underlying determinants
1.2.3 Consequences on health due to risk factors
1.2.4 Access to healthcare
1.3 The economic impact of chronic diseases
1.4 Summary
2: Chronic diseases in China
2.1 The nutritional transition
2.2 Behavioural risk factors
2.3 Conditions in need of pharmaceutical drugs
- 2.3.1 Hypertension
2.3.2 Obesity and overweight people
2.3.3 Diabetes
2.3.4 Tobacco Usage
2.4 Rural and urban areas
2.5 Summary
3: Overview of China’s healthcare system
3.1 Weakened government role, communication, and control
3.2 Fragmentation of healthcare system
3.3 Market forces
3.4 Economic and healthcare costs to China
- 3.4.1 Health insurance
3.5 Commercialization of healthcare
3.6 Summary
4: Business opportunities in China’s pharmaceutical market
4.1 Background
4.2 Entry barriers for pharmaceutical MNCs
- 4.2.1 A changing market
4.2.2 Clinical research opportunities
4.2.3 Intellectual property rights
4.2.4 Bribery and Corruption
4.2.5 Tax incentives
4.2.6 Drug Pricing
4.2.7 Complex distribution channels
4.2.8 Strategic regions in China
4.2.9 Financial reporting
4.3 Bargaining power of buyers
4.4 Threat of substitutes
4.5 Bargaining power of suppliers
4.6 Rivalry within the environment
4.7 Summary
5: Recommendations
5.1 Key success factors for doing business in China
- 5.1.1 Organizational Behaviour and Competencies
5.2 Chronic disease prevention
5.3 Summary
6: Conclusion
References
